Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Short-term Investments (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Short-term Investments for 5 consecutive years, with $331.5 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 31.2% to $331.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $331.5 million through Dec 2025, up 31.2% year-over-year, with the annual reading at $331.5 million for FY2025, 31.2% up from the prior year.
  • Short-term Investments hit $331.5 million in Q4 2025 for Krystal Biotech, down from $338.5 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $338.5 million in Q3 2025 to a low of $1.2 million in Q1 2021.
  • Historically, Short-term Investments has averaged $196.5 million across 5 years, with a median of $207.4 million in 2022.
  • Biggest five-year swings in Short-term Investments: skyrocketed 13147.52% in 2022 and later fell 19.98% in 2023.
  • Year by year, Short-term Investments stood at $96.8 million in 2021, then skyrocketed by 124.34% to $217.3 million in 2022, then dropped by 19.98% to $173.8 million in 2023, then skyrocketed by 45.33% to $252.7 million in 2024, then surged by 31.2% to $331.5 million in 2025.
  • Business Quant data shows Short-term Investments for KRYS at $331.5 million in Q4 2025, $338.5 million in Q3 2025, and $328.2 million in Q2 2025.